Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 266Lung Neoplasms 102Adenocarcinoma of Lung 28Mesothelioma, Malignant 24Mesothelioma 22Neoplasms 18Meningeal Carcinomatosis 18Brain Neoplasms 16Head and Neck Neoplasms 14Neoplasm Metastasis 13Ovarian Neoplasms 9NSCLC 9Colorectal Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 8Breast Neoplasms 7Recurrence 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma 5Esophageal Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma 4Non-squamous Non-small Cell Lung Cancer 4Non-small Cell Lung Cancer Metastatic 4Fallopian Tube Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × Pemetrexed × Clear all
NCT00424723 2010-08-12

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡